Biomarkers of therapeutic response in melanoma and renal cell carcinoma: Potential inroads to improved immunotherapy

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2583-2585

  Kirkwood, John M ^a   Tarhini, Ahmad A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CARBONATE DEHYDRATASE IX; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FIBRONECTIN; INTERLEUKIN 2; IPILIMUMAB; RECOMBINANT INTERLEUKIN 2; STAT1 PROTEIN; STAT2 PROTEIN; STAT5 PROTEIN; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; ANTINEOPLASTIC AGENT; IL2 PROTEIN, HUMAN; RECOMBINANT PROTEIN; VEGFA PROTEIN, HUMAN;

AUTOIMMUNE THYROIDITIS; CANCER IMMUNOTHERAPY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EDITORIAL; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MELANOMA; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; THROMBOCYTOPENIA; VITILIGO; BLOOD; IMMUNOTHERAPY; KIDNEY TUMOR; METASTASIS; METHODOLOGY; MORTALITY; NOTE; PATHOLOGY; PATIENT SELECTION; PREDICTION AND FORECASTING; PROTEOMICS; REPRODUCIBILITY; RISK ASSESSMENT; SKIN TUMOR; TIME; TREATMENT FAILURE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FIBRONECTINS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MELANOMA; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROTEOMICS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SKIN NEOPLASMS; TIME FACTORS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66849083515     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.1540     Document Type: Editorial

References (17)

1. Moschos SJ, Edington HD, Land SR, et al: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171, 2006
2. Wang W, Edington HD, Rao UN, et al: Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 13:1523-1531, 2007
3. Wang W, Edington HD, Jukic DM, et al: Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol Immunother 57:1315-1321, 2008
4. Critchley-Thorne RJ, Yan N, Nacu S, et al: Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4:e176, 2007
5. Gogas H, Ioannovich J, Dafni U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718, 2006
6. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13:2422-2428, 2007
7. Panelli MC, Wang E, Phan G, et al: Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 3:RESEARCH0035, 2002
8. Sabatino M, Kim-Schulze S, Panelli MC: Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27:2645-2652, 2009
9. Soubrane C, Mouawad R, Rixe O, et al: Changes in circulating VEGF-A levels related to clinical response during biochemotherapy in metastatic malignant melanoma. J Clin Oncol 22:717s, 2004 (suppl; abstr 7531)
10. Soubrane C, Mouawad R, Sultan V, et al: Soluble VEGF-A and lymphangiogenesis in metastatic malignant melanoma patients. J Clin Oncol 24:465s, 2006 (suppl; abstr 8049)
11. Mouawad R, Meric JB, Spano JP, et al: Relationship of soluble VEGF-C and VEGF-D with clinicopathological parameters in metastatic malignant melanoma patients treated by biochemotherapy. J Clin Oncol 23:720s, 2005 (suppl; abstr 7540)
12. Mehnert JM, McCarthy MM, Aziz SA, et al: VEGF, VEGFR1, and VEGFR2 expression in melanoma. J Clin Oncol 25:477s, 2007 (suppl; abstr 8520)
13. Duff SE, Li C, Jeziorska M, et al: Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89:426-430, 2003
14. Paley PJ, Staskus KA, Gebhard K, et al: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98-106, 1997
15. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
16. Tatsumi T, Kierstead LS, Ranieri E, et al: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619-628, 2002
17. Atkins MB: Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 12:877-902, viii, 1998